Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead [Yahoo! Finance]
Corbus Pharmaceuticals (NASDAQ:CRBP) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference [Yahoo! Finance]
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms [Seeking Alpha]